ArticleInfection and immunity2004
Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen.
Article in Infection and immunity, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 57 citations in OpenAlex.
- Effects of human immunoglobulins onmBio · 2026Article
- Reduced growth and biofilm formation at high temperatures contribute to Cryptococcus deneoformans dermatotropism.Disease models & mechanisms · 2025Article
- Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors.ImmunoTargets and therapy · 2025Review
- Article
- GXMR-CAR containing distinct GXM-specific single-chain variable fragment (scFv) mediated the cell activation againstBioengineered · 2023Article
- Glucuronoxylomannan intranasal challenge prior to Cryptococcus neoformans pulmonary infection enhances cerebral cryptococcosis in rodents.PLoS pathogens · 2023Article
- Monoclonal Antibodies against Cell Wall Chitooligomers as Accessory Tools for the Control of Cryptococcosis.Antimicrobial agents and chemotherapy · 2021Article
- Comparison of a Lateral Flow Assay and a Latex Agglutination Test for the Diagnosis of Cryptococcus Neoformans Infection.Current microbiology · 2021Article
- X-linked immunodeficient (XID) mice exhibit high susceptibility to Cryptococcus gattii infection.Scientific reports · 2021Article
- Human gut mycobiota tune immunity via CARD9-dependent induction of anti-fungal IgG antibodies.Cell · 2021Article
- Remodeling of theVaccines · 2020Article
- Immunotherapy against Systemic Fungal Infections Based on Monoclonal Antibodies.Journal of fungi (Basel, Switzerland) · 2020Review
- A Plumieridine-Rich Fraction FromFrontiers in microbiology · 2020Article
- Reassessing therapeutic antibodies for neglected and tropical diseases.PLoS neglected tropical diseases · 2020Review
- Reduced phagocytosis and killing of Cryptococcus neoformans biofilm-derived cells by J774.16 macrophages is associated with fungal capsular production and surface modification.Fungal genetics and biology : FG & B · 2019Article
- Methamphetamine Impairs IgG1-Mediated Phagocytosis and Killing of Cryptococcus neoformans by J774.16 Macrophage- and NR-9640 Microglia-Like Cells.Infection and immunity · 2019Article
- Cryptococcal Traits Mediating Adherence to Biotic and Abiotic Surfaces.Journal of fungi (Basel, Switzerland) · 2018Review
- The Crucial Role of Biofilms in Cryptococcus neoformans Survival within Macrophages and Colonization of the Central Nervous System.Journal of fungi (Basel, Switzerland) · 2017Review
- A Monoclonal Antibody to Cryptococcus neoformans Glucuronoxylomannan Manifests Hydrolytic Activity for Both Peptides and Polysaccharides.The Journal of biological chemistry · 2017Article
- B cells and antibodies in the defense against Mycobacterium tuberculosis infection.Immunological reviews · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Cryptococcus neoformans releases capsular polysaccharide in the supernatant of liquid cultures and in tissues. Significantly less glucuronoxylomannan (GXM) was released by C. neoformans in the presence of capsule-binding monoclonal antibody (MAb). MAb-mediated inhibition of GXM release may be another mechanism by which humoral immunity can mediate protection against this pathogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.